Clinical Efficacy Analysis of Rituximab in the Treatment of Minimal Change Disease in Adults
Objective:To evaluate the efficacy and safety of rituximab(RTX)in the treatment of minimal change disease(MCD)in adults.Methods:It was a single-center retrospective study conducted at the Department of Nephrology,Shenzhen Second Peoples Hospital.Adult MCD patients who received rituximab treatment from January 1,2020,to December 31,2022,were includ-ed.The selected patients received RTX at a dose of 1 000 mg twice,with a 2-week interval between doses.Clinical data and labora-tory examinations were collected.The main observation indicators were remission and relapse of kidney disease.The differences in the rate of urinary protein reduction and serum albumin increase between patients achieving complete remission and those who did not were analyzed using generalized additive mixed models.Results:There were 25 patients included in this study,17 males.After RTX treat-ment,25 patients completed the 6-month follow-up,with a remission(CR+PR)rate of 88％and a complete remission rate of 72％.The median time to acheive complete remission was 4 months.The non-remission rate was 12％.13 patients completed the 12-month follow-up,with a remission(CR+PR)rate of 96％,a complete remission rate of 84％,and a non-remission rate of 4％.In the mean follow-up time of(13.25±6.47)months after achieving complete remission,one patient experienced a relapse 10 months after achieving complete remission with RTX,and then abtained complete remission again 1 month after adding 1 g of RTX,and the rest did not experience any relapse.Patients with a faster rate of urinary protein reduction and serum albumin increase were more likely to achieve complete remission.Conclusion:Rituximab treatment effectively induces complete or partial clinical remission in adult MCD patients.It has a low short-term relapse rate and demonstrates good efficacy and safety.Therefore,rituximab can be considered as a new treatment option for adult MCD patients.
万方数据
维普
